Press Release
CGBIO attains CE certification of Europe for HA filters
필러 제품 이미지

‘CGBIO has acquired two CE markings for hyaluronic acid (HA) fillers, Giselleligne and VOM’, CGBIO officials announced on May 24, 2021.

These two HA fillers are used for correcting defective soft tissues in the face. They contain a local anesthetic that can alleviate pain transiently. CGBIO owns 10 CE markings, including these two CE certifications.

Based on a patented technology, Giselleligne is an anesthetic premium filler formulated by using small particles of HA hydrogel. The main feature of this filler is its multi-layered formula in which a pulling force within the filler material is further strengthened while smoothing the neighboring area. When injected, the filler allows for smoothing of the affected area. The efficacy, safety, and superiority of Giselleligne were firmly established through animal experiments last year since the filler was proven to be able to stimulate the production of natural skin components such as collagen and elastin. In 2019, Giselleligne was launched after obtaining approval from the National Medical Products of China. CGBIO plans to file the NDA application for Giselleligne to the U.S. Food and Drug Administration.